| Emelina A Arocha Md Pa | |
|
717 Ponce De Leon Blvd Ste 327 Coral Gables FL 33134-2050 | |
| (305) 445-5994 | |
| (305) 445-5999 |
| Full Name | Emelina A Arocha Md Pa |
|---|---|
| Speciality | Psychiatry & Neurology |
| Location | 717 Ponce De Leon Blvd Ste 327, Coral Gables, Florida |
| Authorized Official Name and Position | Emelina Acacia Arocha (MEDICAL DOCTOR) |
| Authorized Official Contact | 3054455994 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Emelina A Arocha Md Pa 717 Ponce De Leon Blvd Ste 327 Coral Gables FL 33134-2050 Ph: (305) 445-5994 | Emelina A Arocha Md Pa 717 Ponce De Leon Blvd Ste 327 Coral Gables FL 33134-2050 Ph: (305) 445-5994 |
| NPI Number | 1407980485 |
|---|---|
| Provider Enumeration Date | 03/14/2007 |
| Last Update Date | 11/30/2007 |
| Medicare PECOS PAC ID | 4486638384 |
|---|---|
| Medicare Enrollment ID | O20050629000627 |
News Archive
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced the pricing of its previously announced underwritten public offering of 11,500,000 units of its securities at a public offering price of $0.41 per unit.
The American Association of Neuromuscular & Electrodiagnostic Medicine submitted a comment letter to the Centers for Medicare & Medicaid Services on August 21 regarding its proposed rule changes on Medicare payment and delivery reform enacted by MACRA.
AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).
Patients who survive a brief cardiac arrest and who appear neurologically intact should nonetheless receive a detailed neuropsychological assessment before being discharged, suggests a joint study by researchers at Baycrest's Rotman Research Institute and Israel's Rambam Medical Center.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407980485 | NPI | - | NPPES |
| 48896 | Other | FL | BLUECROSS/BLUESHIELD PROV |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | ME89118 (Florida) | Primary |
| Provider Name | Emelina Acacia Arocha |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1356343016 PECOS PAC ID: 6608850516 Enrollment ID: I20040617000587 |
News Archive
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced the pricing of its previously announced underwritten public offering of 11,500,000 units of its securities at a public offering price of $0.41 per unit.
The American Association of Neuromuscular & Electrodiagnostic Medicine submitted a comment letter to the Centers for Medicare & Medicaid Services on August 21 regarding its proposed rule changes on Medicare payment and delivery reform enacted by MACRA.
AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).
Patients who survive a brief cardiac arrest and who appear neurologically intact should nonetheless receive a detailed neuropsychological assessment before being discharged, suggests a joint study by researchers at Baycrest's Rotman Research Institute and Israel's Rambam Medical Center.
› Verified 8 days ago
News Archive
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced the pricing of its previously announced underwritten public offering of 11,500,000 units of its securities at a public offering price of $0.41 per unit.
The American Association of Neuromuscular & Electrodiagnostic Medicine submitted a comment letter to the Centers for Medicare & Medicaid Services on August 21 regarding its proposed rule changes on Medicare payment and delivery reform enacted by MACRA.
AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).
Patients who survive a brief cardiac arrest and who appear neurologically intact should nonetheless receive a detailed neuropsychological assessment before being discharged, suggests a joint study by researchers at Baycrest's Rotman Research Institute and Israel's Rambam Medical Center.
› Verified 8 days ago
Mindful Milestones Theraphy Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4483 Sw 8th St, Coral Gables, FL 33134 Phone: 786-975-8577 | |
Martha Bofill & Associates Psy Corp Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 747 Ponce De Leon Blvd, Suite 501, Coral Gables, FL 33134 Phone: 786-587-2617 Fax: 305-454-0156 | |
Abanzamos, Llc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 95 Merrick Way Fl 3, Coral Gables, FL 33134 Phone: 305-778-9959 | |
T. R. Treese, M.d., P.a. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4950 South Lejeune Road, Suite E, Coral Gables, FL 33146 Phone: 305-667-7171 Fax: 305-667-7077 | |
Nouveau Psychiatric Services Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4505 W Flagler St, Ste 201, Coral Gables, FL 33134 Phone: 305-444-3333 | |
Margarita Borda Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 260 Palermo Ave Ste 12, Coral Gables, FL 33134 Phone: 305-898-6607 | |
Aynar Alvarez, Lmft, Pa Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 350 Sevilla Ave Ste 204, Coral Gables, FL 33134 Phone: 786-548-0547 |